Chemotherapy-induced febrile neutropenia: About 186 episodes ·Clinical, microbiological and therapeutic characteristics

##plugins.themes.academic_pro.article.main##

Masmoudi Safia
Afef Khanfir
Smida Maalej-Mezghan
Adnen Hammami
Mounir Frikha

Abstract

Background: One of the major side effects of anti-proliferative treatment is their medullar toxicity. This toxicity is particularly important in neutrophils and leads to a neutropenia. Fever during these episodes of neutropenia is a frequent complication but remains of indeterminate origin in 60% of cases. It’s a medical emergency because of rapid evolution and a significant increase in mortality up to 10%. Thus, these episodes should be prevented and treated in priority with un empiric and large spectrum antibiotherapy, taking into account the bacterial ecology of each hospital.
Aim: The aim of this study was to determinate the clinical, therapeutic and evolutive characteristics of febrile neutropenia (FN). Methods: This retrospective study concerned 186 episodes of FN in 136 patients treated for solid tumors and lymphoma in the department of medical oncology of Sfax from january 2006 to December 2010.
Results: Mean age was 40 years (1 to 81) and sex ratio at 0.97. They were trated mainly solid tumors in 86.02%. Median time to onset of FN was 11 days and the mean duration of neutropenia was 5 days. 24.2% had a neutrophil count (ANC) <100 / mm3. Fever was clinically documented in 33.87%. Patients have mainly ORL clinical manifestations (38.46%) and specially mucositis (50%). Only 17.2% of cases were microbiologically documented and a bacteria was isolated in 76.46% of them in blood cultures, Gram-negative bacilli (GNB) accounted for the majority of organisms isolated in different samples in 66.66% of cases. Enterobacteriaceae were the most frequent dominated by Klebsiella spp, followed by Escherichia coli. Pseudomonas aeruginosa ranked second after the Enterobacteriaceae (21.21%). The Gram-positive cocci (GPC) were found in 24.24% mainly Staphylococcus aureus. The first line of empirical antibiotic therapy was associated in 88.7% of ceftazidime and amikacin or a fluoroquinolone that has to have an efficiency of 72.12%. The rate of death due to infection in our series was 9.14%.
Conclusion: Our results are consistent with data in the literature concerning the short duration of neutropenia, causing fever and mortality, but our bacterial epidemiology is different from the current literature, where there is a predominance of CGP unlike our predominantly the BGN. And prescribing empiric antibiotic therapy must take into account the epidemiological and ecological particularities of each country, each hospital or each department.

Keywords:

Fever, neutropenia, chemotherapy, infection, antibiotic, bacteriology

##plugins.themes.academic_pro.article.details##

References

  1. Ray-Coquard I, Borg C, Bachelot T, et al. Prognostic factors for febrile neutropenia. Bull Cancer 2006 ; 93 :501-6
  2. Hughes WT, Armstrong D, Bodey GP, et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997; 25:551-73
  3. Even.C, Taillade. L, Spano J.P, Vignot.S. Neutropénie fébrile chez le patient adulte atteint de tumeur solide : revue de la littérature pour une gestion rationnelle et optimale. Bull Cancer 2010 ; 9 :547-57
  4. Vernant JP, Thibault M, Cordonnier C, et al. Bacterial septicemia in neutropenia patients. Ann Intern Med 1983;134:629-35.
  5. Lyman GH, Michels SL, Reynolds MW, Barron R, Tomic KS, Yu J. Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer 2010;116:555-63.
  6. Dutronc. H, Billhot. M, Dupon. M, et al. Prise en charge de 315 épisodes neutropéniques fébriles dans un centre anticancéreux. Med Mal Infect 2009;39:388-393.
  7. Gharbi. O, Ben Hadj Hassen. S, Kaabia. K, et al. Les neutropénies fébriles chimio-induites :à propos de 200 épisodes Profil clinique, microbiologique et thérapeutique. Pathol Biol 2008;56:154-157
  8. Cordonnier C, Herbrecht R, Buzyn A, et al. Risk factors for Gram-negative bacterial infections in febrile neutropenia. Haematologica 2005;90:1102- 9
  9. Kanamaru A, Tatsumi Y. Microbiological Data for Patients with Febrile Neutropenia. Clin Infect Dis 2004; 39:7-10.
  10. Klastersky J, Awada A, Paesmans M, Aoun M. Febrile neutropenia: a critical review of the initial management. Crit Rev Oncol Hematol 2011;78:185-94.
  11. Mkaouar D, Mahjoubi F, Mezghani S, Znazen A, Ktari S, Hammami A. Resistance to third generation cephalosporins in Sfax hospitals, Tunisia (1999-2005). Med Mal Infect 2008;38:293-8
  12. Marra F, Reynolds R, Stiver G, et al. Piperacillin/tazobactam versus imipenem: a double-blind, randomized formulary feasibility study at a major teaching hospital. Diagn Microbiol Infect Dis 1998;31:355-68.
  13. Böhme A, Shah PM, Stille W, Hoelzer D. Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study. Eur J Med Res 1998;3:324-30.
  14. De Naurois J, Novitzky-BI, Gill MJ, Marti FM, Cullen MH, Roila F. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol 2010; 21:252-6.
  15. Cometta A, Zinner S, de Bock R, et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents and Chemother 1995;39:445-52.
  16. Marie JP, Vekhoff A, Cony-Makhoul P, et al. Piperacilline/tazobactam combination+amikacin versus ceftazidime+amikacin in patients with neutropenia and fever. An open multicenter study. Presse Med 1995;24:397-401
  17. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011;52:56-93.
  18. Kontoyiannis DP, Mantadakis E, Samonis G. Systemic mycoses in the immunocompromised host: an update in antifungal therapy. J Hosp Infect 2003;53:243-58.
  19. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992;10:316-22.
  20. Cometta A, Kern WV, De Bock. Vancomycin does not benefit persistently febrile neutropenic people with cancer. Cancer Trea Rev 2004;30:119- 26.
  21. Sipsas NV, Bodey GP, Kontoyiannis DP. Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. Cancer 2005;103:1103-13.